Text Size

Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00518661
First received: August 17, 2007
Last updated: August 23, 2012
Last verified: August 2012
History of Changes
  Purpose

This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.


Condition
Quinolone Resistance
ESBL
Klebsiella Species
Infection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Risk Factors for Quinolone Resistance Among Extended-Spectrum Beta-Lactamase-Producing Klebsiella Species

Further study details as provided by University of Pittsburgh:

Estimated Enrollment: 500
Study Start Date: August 2007
Estimated Study Completion Date: December 2015
Detailed Description:

This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed. This research is (c) important because identification of risk factors may allow earlier initiation of appropriate therapy in patients infected with these bacteria. Additionally, we will identify whether horizontal spread is responsible for this increasing trend.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

quinolone resistant

Criteria

Inclusion Criteria:

  • must be quinolone resistant among ESBL producing klebsiella species

Exclusion Criteria:

  • Those not meeting entry criteria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00518661

Locations
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Brian Potoski, PharmD University of Pittsburgh
  More Information

No publications provided

Responsible Party: University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00518661     History of Changes
Other Study ID Numbers: PRO07070356, investigator funding
Study First Received: August 17, 2007
Last Updated: August 23, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
quinolone resistance
ESBL
Klebsiella species
Infection

Additional relevant MeSH terms:
Klebsiella Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on May 22, 2013